Logo

CuraGen, Pfizer in Toxicogenomics Deal

Jan 07, 2003

NEW YORK, Jan. 7-CuraGen is working with Pfizer to apply toxicogenomics screening and protein pathway mapping for the pharmaceutical company's drug candidates, CuraGen said today.

 

CuraGen researchers will use the company's Predictive Toxicogenomics Screen early on in the drug development process to select promising compounds. The company will also supply its protein pathway mapping techniques to explore mechanisms and activity of drugs in later development stages.

 

Financial details of the agreement were not disclosed.

 

For further information, see the press release.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.